Patent SG-11201900228Y-A (SG)
Title: Administration and dosage of diaminophenothiazines
Inventor: WISCHIK CLAUDE MICHEL
IPC: A61P25/28
Filed: 2017-07-25
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/019823 Al 01 February 2018 (01.02.2018) WIP0 I PCT (51) International Patent Classification: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, A61K 31/5415 (2006.01) A61P 25/28 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (21) International Application Number: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, PCT/EP2017/068749 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (22) International Filing Date: KM, ML, MR, NE, SN, TD, TG). 25 July 2017 (25.07.2017) Declarations under Rule 4.17: (25) Filing Language: English — of inventorship (Rule 4.17(iv)) (26) Publication Language: English Published: (30) Priority Data: — with international search report (Art. 21(3)) 1612863.9 25 July 2016 (25.07.2016) GB 1710382.1 29 June 2017 (29.06.2017) GB (71) Applicant: WISTA LABORATORIES LTD. [SG/SG]; 25 Bukit Batok Crescent, The Elitist #06-13, Singapore 658066 (SG). (71) Applicant (for MG only): HARRINGTON, Charles Robert [GB/GB]; WisTa Laboratories Ltd., Institute of Medical Sciences, Forresterhill, Aberdeen Aberdeenshire AB25 2ZD (GB). (72) Inventors: WISCHIK, Claude Michel; WisTa Labora- tories Ltd., Institute of Medical Sciences, Forresterhill, Aberdeen Aberdeenshire AB25 2ZD (GB). SCHELTER, Bjorn Olaf; University of Aberdeen, Institute for Complex Systems and, Mathematical Biology, Meston Walk, Ab- erdeen Aberdeenshire AB24 3UE (GB). WISCHIK, Da- mon Jude; Cambridge Big Data, Cavendish Laboratory, J.J. Thomson Avenue, Cambridge Cambridgeshire CB3 OHE (GB). STOREY, John Mervyn David; c/o WisTa Labo- ratories Ltd., Department of Chemistry, Meston Walk, Old Aberdeen, Aberdeenshire AB24 3UE (GB). = (74) Agent: KREMER, Simon et al.; Mewburn Ellis LLP, City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB). Designated States indicated, (81) (unless otherwise for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, DE, DJ, DK, DM, DO, CA, CH, CL, CN, CO, CR, CU, CZ, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 1-1 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. N (84) Designated States (unless otherwise indicated, for every GC kind of regional protection available): ARIPO (BW, GH, 0\ GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 1-1 0 00 (54) Title: ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES 1-1 0 (57) : The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)- ei containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction 0 with symptomatic treatments based on modulation of acetylcholinesterase levels.